NCT07318831招募中2 期
A Phase II Trial of Chidamide Combined With Dinutuximab Beta, Irinotecan, and Temozolomide for Refractory or Relapsed Neuroblastoma in Children
Tianjin Medical University Cancer Institute and Hospital1 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2026年1月6日最近更新:
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 27
- 试验地点
- 1
- 主要终点
- Objective Response Rate（ORR）
研究概览
简要总结
This is a Phase II clinical trial investigating the effectiveness and safety of a four-drug combination-Chidamide, Dinutuximab Beta, Irinotecan, and Temozolomide-for children with relapsed or refractory neuroblastoma. The primary goal is to evaluate how well this regimen works to control the cancer, while the secondary goal is to closely monitor its safety and side effects in these young patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with histologically diagnosed neuroblastoma, defined according to the International Neuroblastoma Risk Group (INRG) classification system or the Chinese expert consensus/guideline for pediatric neuroblastoma.
- •Patients with relapsed or refractory neuroblastoma. Relapsed: any patient with recurrent neuroblastoma. Refractory: patients showing an inadequate response (partial response, minor response, or stable disease) to prior therapy, leading to progression.
- •Prior treatment with epigenetic drugs (e.g., HDAC inhibitors, DNA methylation inhibitors) or GD2 monoclonal antibodies does not affect eligibility for this study.
- •Presence of evaluable disease.
- •Performance Status: Lansky score ≥50%, Karnofsky score ≥50%, or ECOG score ≤
- •Life expectancy ≥12 weeks.
- •Bone marrow function: Without bone marrow disease: Platelets ≥75×10⁹/L, Absolute Neutrophil Count (ANC) ≥0.75×10⁹/L, Hemoglobin ≥8 g/dL (transfusion allowed). With bone marrow disease: Platelets ≥50×10⁹/L, ANC ≥0.5×10⁹/L, Hemoglobin ≥8 g/dL (transfusion allowed).
- •Renal function: No clinically significant proteinuria (morning urine dipstick <2+). If proteinuria ≥2+ is detected, the protein-to-creatinine (Pr/Cr) ratio must be <0.5 or 24-hour protein excretion must be <0.5 g.
- •Serum creatinine ≤1.5 × ULN; if higher, the calculated glomerular filtration rate (by radioisotope method) must be ≥60 mL/min/1.73 m².
- •Hepatic function: AST or ALT ≤2.5 × ULN and total bilirubin ≤1.5 × ULN. In the presence of liver metastases: AST or ALT ≤5 × ULN and total bilirubin ≤2.5 × ULN.
- •Cardiac function: Left ventricular shortening fraction ≥29% on echocardiogram.
- •Coagulation: For patients not on anticoagulation therapy: INR ≤1.5 and APTT ≤1.5 × ULN. Anticoagulation is allowed if INR or APTT is within the therapeutic range (per institutional standards) and the patient has been on a stable dose for at least two weeks prior to study enrollment.
- •Oxygen saturation >94% on room air.
- •Ability to comply with the study visit schedule and other protocol requirements.
排除标准
- •Patients with CTCAE v5.0 Grade 3 or higher toxicities involving hearing impairment, hematologic disorders, hepatic, or renal diseases.
- •Patients with CTCAE v5.0 Grade 2 or higher neurotoxicity.
- •Major surgical procedure within 14 days prior to the first dose of the study drug.
- •Severe infection (requiring IV antibiotics, antifungals, or antivirals) within one week prior to treatment, or unexplained fever >38.5°C during screening or before the first dose.
- •Congenital or acquired immunodeficiency, or active infectious diseases such as HIV or active hepatitis (with transaminase levels not meeting inclusion criteria; HBV DNA ≥1000 IU/mL; HCV RNA ≥1000 IU/mL). Chronic HBV carriers with HBV DNA <2000 IU/mL may be enrolled if they receive concurrent antiviral therapy during the trial.
- •Any concomitant condition that, in the investigator's judgment, seriously jeopardizes patient safety, may confound the study results, or could impede the patient's completion of the study.
研究组 & 干预措施
Chidamide
Experimental
干预措施: Chidamide Combined with Dinutuximab Beta, Irinotecan, and Temozolomide (Drug)
结局指标
主要结局
Objective Response Rate（ORR）
时间窗: From enrollment to the end of treatment at 10 weeks
次要结局
- Duration of Response(DOR)(From enrollment to the end of treatment at 10 weeks)
- Progression-Free Survival(PFS)(From enrollment to the end of treatment at 10 weeks)
- Event-Free Survival(EFS)(From enrollment to the end of treatment at 10 weeks)
- Overall Survival (OS)(From enrollment to the end of treatment at 10 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AMLNCT07304232Institute of Hematology & Blood Diseases Hospital, China134
招募中
2 期
Phase 2 Trial to determine the safety and efficacy of simultaneous treatment with ruxolitinib and extracorporeal photopheresis for patients with steroid-refractory chronic Graft-versus-Host-Disease (SR-cGvHD) - RUX-ECP2023-507754-33-00Medical Center - University Of Freiburg40
招募中
2 期
A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes MellitusNCT07303803Shanghai Jiao Tong University School of Medicine300
尚未招募
2 期
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic CancerNCT07301229Shanghai Henlius Biotech100
招募中
2 期
A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung CancerAdvanced Lung CancerNCT07309276Shanghai Junshi Bioscience Co., Ltd.864